Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...